Phase II trial of galiximab (anti-CD80 monoclonal antibody) plus rituximab (CALGB 50402): Follicular Lymphoma International Prognostic Index (FLIPI) score is predictive of upfront immunotherapy responsiveness.

Overview

authors

Leonard, John P
Jung, S
Johnson, J L
Hsi, E D
Byrd, J C
Cheson, B D

publication date

November 1, 2018

published in

Annals of oncology : official journal of the European Society for Medical Oncology Journal

Identity

PubMed Central ID

PMC6290880

Scopus Document Identifier

85099722482

Digital Object Identifier (DOI)

10.1093/annonc/mdx812

PubMed ID

29390097

Additional Document Info

has global citation frequency

1

volume

29

issue

11